New Astrazeneca patent mentions GSK3 Inhibitor

[LinuxCavalier]

GSK3 phosphorylates and degrades ?-catenin. ?-catenin is an effector of the pathway for keratonin synthesis, ?-catenin stabilisation may be lead to increase hair development. Mice expressing a stabilised ?-catenin by mutation of sites phosphorylated by GSK3 undergo a process resembling de novo hair morphogenesis (Gat et al., Cell, 1998, 95(5): 605-14)). The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. Thus GSK3 inhibition may offer treatment for baldness.

I wonder if follica is experimenting using this as well...

http://www.wipo.int/pctdb/en/fetch.jsp?SEARCH_IA=SE2008050357&DBSELECT=PCT&C=10&TOTAL=30200&IDB=0&TYPE_FIELD=256&SERVER_TYPE=19-10&QUERY=(DE%2Fhair)+&ELEMENT_SET=B&START=26&SORT=41250829-KEY&RESULT=26&DISP=25&FORM=SEP-0%2FHITNUM%2CB-ENG%2CDP%2CMC%2CAN%2CPA%2CABSUM-ENG&IDOC=1588731&IA=SE2008050357&LANG=ENG&DISPLAY=STATUS